Company History

Aniva International was established in early 2013, in the middle of the most severe financial crisis that hit Greece for a generation. Despite the disruptive political and business environment, a team of professional people who believed in doing things differently set out with the objective of creating a collaborative platform that could generate long-standing value for its partners. Soon after, the first office of Aniva opened in Athens followed by affiliates and associate offices in various parts of the world.

Since its inception, Aniva International has put in place an open and interactive organization that encompasses its customers and suppliers, with the aim to serve the health care market with clinically validated products and brands based on natural biomolecules.

In the first year of its creation, it managed to develop and establish its first 2 brands, Anantra and Anivagene, in more than 20 countries worldwide.

By middle of 2014 Aniva in-licensed the patent and then developed, manufactured and introduced into European markets the first world-patented OTx for MS and other neurodegenerative diseases.

In order to establish its presents in the world market, Aniva decided to participate in major international excibitions of our sector.

To that end we have been excibiting constantly since 2017 in Vitafoods Europe with stand, where in 2024 our stand it was rewarded with THE GOLD PRIZE.

In 2017, Aniva International set up its first fully operational commercial subsidiary in Cyprus in order to cover the needs of the Cypriot market. The company is located in downtown Nicosia and it is comprised of large team of medical as well as sales reps.

By the end of 2018 Aniva International set up its 2nd affiliate for the Greek market with full-fledged sales and marketing team in order to meet the needs of the ever-growing numbers of chronic & autoimmune diseases patients.

In the last few years Aniva sets foot into the rheumatology health care area, which is becoming a pivotal specialty in dealing with the autoimmune patients, and it’s proud to introduce to the market the first product for Dry-Eye disease in Sjogren Syndrome patients and the first product for Fibromyoalgia, as well as a product for management of Arthritis.

Furthermore 2023, Aniva expanded its Anivagene portfolio with the development of the Face line based on functional ingredients with enhanced cosmetic benefits.

In 2024 Anivagene true to its mission to provide holistic approach to hair and skin needs introduced its first Nutricosmetic product marks the beginning of new Beauty from within product range.